- Home
- / Acasti Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Acasti Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$3.2
2024-10-29
Market Capitalization
$34.2 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 17, 2025
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CAD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 196.0K | ||||||
| Cost of goods sold | 76.0K | ||||||
| Gross profit | 120.0K | ||||||
| Gross profit margin, % | 61.2% | ||||||
| Operating expense total | 17.0M | 45.0M | 24.4M | 10.8M | 15.3M | 18.1M | 12.8M |
| Depreciation and amortization | 2.7M | 5.3M | 34.0M | 11.0K | |||
| EBITDA | (17.0M) | (45.0M) | (24.4M) | (10.7M) | (15.3M) | (18.1M) | (12.8M) |
| EBITDA margin, % | -5467.3% | ||||||
| EBIT | (20.0M) | (45.0M) | (24.4M) | (16.0M) | (10.0M) | (52.1M) | (12.9M) |
| EBIT margin, % | -8166.3% | ||||||
| Interest income | 72.0K | 475.0K | 336.0K | 107.0K | 77.0K | 246.0K | 911.0K |
| Interest expense | 1.5M | 6.7M | 293.0K | 2.7M | |||
| Pre tax profit | (21.5M) | (51.6M) | (25.5M) | (19.7M) | (10.5M) | (52.0M) | (14.7M) |
| Income tax expense | (648.0K) | (9.5M) | (1.8M) | ||||
| Net Income | (21.5M) | (51.6M) | (25.5M) | (19.7M) | (9.8M) | (42.4M) | (12.9M) |